Riskpilot← Back to searchSign inGet full accessTTA Covid SPV AB
ABActiveOrg 5593117251Bergskroken 10 Lgh 1701Research and experimental development on natural sciences and engineering · NACE 7210Est. 20210 employees
Revenue 2024
SEK 0
EBITDA margin
—
-75% vs 2023
Equity ratio
98.3%
Financial strength
Net profit 2024
SEK -150K
-491% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -285K | -75% |
| Net profit | SEK -150K | -491% |
| Total assets | SEK 19,8M | +0% |
| Equity | SEK 19,4M | -1% |
| Employees | 0 | — |
Legal name
TTA Covid SPV AB
Org number
5593117251
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
13 april 2021
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget ska sälja utbildning, forskning och utvecklingsprojekt inom biovetenskap, äga och förvalta aktier och andra immateriella tillgångar, samt därmed förenlig verksamhet.
Address
Bergskroken 10 Lgh 1701
Email
mikael.kubista@xanadu.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 16 | 0 |
| Staff expenses | — | — | — | — |
| EBITDA | 19 425 | −1 | −163 | −285 |
| Depreciation & amort. | −0 | −0 | — | — |
| EBIT | 19 425 | −1 | −163 | −285 |
| Net financials | — | 109 | 224 | 135 |
| Profit before tax | 19 425 | 107 | 61 | −150 |
| Tax | −4 002 | −22 | −23 | — |
| Net profit | 15 423 | 85 | 38 | −150 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 34 795 | 34 587 | 19 736 | 19 761 |
| Equity | 30 448 | 30 534 | 19 574 | 19 424 |
| Long-term debt | 0 | 0 | — | — |
| Short-term debt | 4 346 | 4 054 | 162 | 337 |
| Total debt | 4 346 | 4 054 | 162 | 337 |
EBITDA margin
-28495600.0%
This company
15.8%
Market median
-180351999% vs market
20212024
Equity ratio
98.3%
This company
38.2%
Market median
+157% vs market
20212024
Return on equity
-0.8%
This company
18.4%
Market median
-104% vs market
20212024
Net profit margin
-14970600.0%
This company
8.1%
Market median
-184822322% vs market
20212024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212024
Debt / equity
0.02×
This company
0.62×
Market median
+97% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-04-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
EC | Audit | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2022 | |
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
| Former (1) | ||
| Board of Directors | 2022 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of TTA Covid SPV AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Eva Chris Nettervik Carlsson | Audit | 0 companies |
| Mikael Kubista | Chairman | 0 companies |
| Gösta Robert Sjöback | Deputy Board Member | 0 companies |
| Neven Zoric | Board of Directors | 0 companies |
| Anders Krister Stefan Johanson | Board of Directors | 0 companies |